Earl J. Crain
About
Earl J. Crain is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Genetics.
According to data from OpenAlex, Earl J. Crain has authored 26 papers receiving a total of 853 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cardiology and Cardiovascular Medicine, 12 papers in Hematology and 9 papers in Genetics. Recurrent topics in Earl J. Crain's work include Blood Coagulation and Thrombosis Mechanisms (12 papers), Atrial Fibrillation Management and Outcomes (11 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers). Earl J. Crain is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (12 papers), Atrial Fibrillation Management and Outcomes (11 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers). Earl J. Crain collaborates with scholars based in United States, Germany and Sweden. Earl J. Crain's co-authors include Pancras C. Wong, Carol A. Watson, Ruth R. Wexler, Robert M. Knabb, Patrick Y. S. Lam, Joseph M. Luettgen, Donald Pinto, Mimi L. Quan, William A. Schumacher and Dietmar Seiffert and has published in prestigious journals such as Circulation, Blood and Journal of Medicinal Chemistry.
In The Last Decade
Earl J. Crain
26 papers receiving 822 citations
Peers
Earl J. Crain
Alexander G. Vandell United States
Benjamin E. Tourdot United States
Stefan Carlsson Sweden
Thomas E. Steinbacher United States
Ugo Cavallari Italy
Tsukasa Ishihara Japan
Christopher L. Heran United States
Yoshiyuki Iwatsuki Japan
Ulrike R. Schwarz Germany
Ann‐Catrine Teger‐Nilsson Sweden
Citations per year, relative to Earl J. Crain Earl J. Crain (= 1×)
peers
Alexander G. Vandell
Countries citing papers authored by Earl J. Crain
Since
Specialization
Citations
This map shows the geographic impact of Earl J. Crain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Earl J. Crain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Earl J. Crain more than expected).
Fields of papers citing papers by Earl J. Crain
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Earl J. Crain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Earl J. Crain. The network helps show where Earl J. Crain may publish in the future.
Co-authorship network of co-authors of Earl J. Crain
This figure shows the co-authorship network connecting the top 25 collaborators of Earl J. Crain. A scholar is included among the top collaborators of Earl J. Crain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Earl J. Crain. Earl J. Crain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wong, Pancras C. & Earl J. Crain. (2022). Calibration and validation of the rabbit model of electrolytic‐mediated arterial thrombosis against the standard‐of‐care anticoagulant apixaban. Pharmacology Research & Perspectives. 10(3). e00963–e00963.
2.
Wong, Pancras C., Earl J. Crain, Jeffrey M. Bozarth, et al.. (2021). Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits. Journal of Thrombosis and Haemostasis. 20(2). 399–408.
3.
Wong, Pancras C., Carol A. Watson, & Earl J. Crain. (2015). The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys. Journal of Thrombosis and Thrombolysis. 41(3). 514–521.
4.
Wong, Pancras C., Mimi L. Quan, Carol A. Watson, et al.. (2015). In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa. Journal of Thrombosis and Thrombolysis. 40(4). 416–423.
5.
Wong, Pancras C., Mimi L. Quan, Carol A. Watson, et al.. (2013). Abstract 9916: Potent Antithrombotic Effect of a Small-molecule, Reversible and Direct Inhibitor of Factor XIa With Minimum Bleeding Time Effect In Rabbit Models of Arterial Thrombosis and Hemostasis. Circulation. 128(suppl_22).
6.
Wang, Tammy C., Jennifer X. Qiao, Charles G. Clark, et al.. (2013). Discovery of diarylurea P2Y1 antagonists with improved aqueous solubility. Bioorganic & Medicinal Chemistry Letters. 23(11). 3239–3243.
7.
Wong, Pancras C., Earl J. Crain, Carol A. Watson, & William A. Schumacher. (2011). A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. Journal of Thrombosis and Thrombolysis. 32(2). 129–137.
8.
Zhang, Donglu, Kan He, Nirmala Raghavan, et al.. (2009). Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. Journal of Thrombosis and Thrombolysis. 29(1). 70–80.
9.
Wong, Pancras C., Carol A. Watson, & Earl J. Crain. (2008). Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits. Journal of Thrombosis and Haemostasis. 6(10). 1736–1741.
10.
Wong, Pancras C., Earl J. Crain, Ruth R. Wexler, et al.. (2008). Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. Journal of Thrombosis and Haemostasis. 6(5). 820–829.
11.
Wong, Pancras C., Earl J. Crain, & Carol A. Watson. (2008). Comparative Antithrombotic and Antihemostatic Effects of the Direct Factor Xa Inhibitors, Apixaban and Rivaroxaban, and the Direct Thrombin Inhibitors, Dabigatran and Lepirudin, in Rabbit Models of Venous Thrombosis and Bleeding Time. Blood. 112(11). 3025–3025.
12.
Wong, Pancras C., Earl J. Crain, Carol A. Watson, et al.. (2007). Razaxaban, a direct factor Xa inhibitor, in combination with aspirin and/or clopidogrel improves low-dose antithrombotic activity without enhancing bleeding liability in rabbits. Journal of Thrombosis and Thrombolysis. 24(1). 43–51.
13.
Wong, Pancras C., Earl J. Crain, Carol A. Watson, et al.. (2007). Platelet Aggregometry and Receptor Binding to Predict the Magnitude of Antithrombotic and Bleeding Time Effects of Clopidogrel in Rabbits. Journal of Cardiovascular Pharmacology. 49(5). 316–324.
14.
Wong, Pancras C., Earl J. Crain, Donald Pinto, & Carol A. Watson. (2007). Dose-Dependent Antithrombotic Effects of Apixaban, an Oral Direct Factor Xa Inhibitor, in Prevention and Treatment of Thrombosis in Rabbit Models of Arteriovenous-Shunt and Venous Thrombosis at Doses That Preserve Hemostasis.. Blood. 110(11). 933–933.
15.
Wong, Pancras C., William A. Schumacher, Carol A. Watson, et al.. (2006). Abstract 631: Nonpeptide Factor XIa (FXIa) Inhibitor. In vitro Kinetic Evaluation and in vivo Studies of BMS-262084 on Arterial Thrombosis and Hemostasis in Rabbits. Circulation. 114.
16.
Wong, Pancras C., Earl J. Crain, Carol A. Watson, et al.. (2002). Nonpeptide Factor Xa Inhibitors III: Effects of DPC423, an Orally-Active Pyrazole Antithrombotic Agent, on Arterial Thrombosis in Rabbits. Journal of Pharmacology and Experimental Therapeutics. 303(3). 993–1000.
17.
Wong, Pancras C., Earl J. Crain, Robert M. Knabb, et al.. (2000). Nonpeptide Factor Xa Inhibitors II. Antithrombotic Evaluation in a Rabbit Model of Electrically Induced Carotid Artery Thrombosis. Journal of Pharmacology and Experimental Therapeutics. 295(1). 212–218.
18.
Wong, Pancras C., Mimi L. Quan, Earl J. Crain, et al.. (2000). Nonpeptide Factor Xa Inhibitors: I. Studies with SF303 and SK549, a New Class of Potent Antithrombotics. Journal of Pharmacology and Experimental Therapeutics. 292(1). 351–357.
19.
Wong, Pancras C., et al.. (1996). ANTITHROMBOTIC ACTIONS OF SELECTIVE INHIBITORS OF BLOOD COAGULATION FACTOR Xa IN RAT MODELS OF THROMBOSIS. Thrombosis Research. 83(2). 117–126.
20.
Wong, Pancras C., Mimi L. Quan, Earl J. Crain, et al.. (1995). Pharmacology of XR510, a Potent Orally Active Nonpeptide Angiotensin II AT1 Receptor Antagonist with High Affinity for the AT2 Receptor Subtype. Journal of Cardiovascular Pharmacology. 26(3). 354–362.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alexander G. Vandell Breakdown of academic impact, for papers by Benjamin E. Tourdot Breakdown of academic impact, for papers by Stefan Carlsson Breakdown of academic impact, for papers by Thomas E. Steinbacher Breakdown of academic impact, for papers by Ugo Cavallari Breakdown of academic impact, for papers by Tsukasa Ishihara Breakdown of academic impact, for papers by Christopher L. Heran Breakdown of academic impact, for papers by Yoshiyuki Iwatsuki Breakdown of academic impact, for papers by Ulrike R. Schwarz Breakdown of academic impact, for papers by Ann‐Catrine Teger‐Nilsson